Page 2 - Fady Ibraham Malik News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fady ibraham malik. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fady Ibraham Malik Today - Breaking & Trending Today

Truist Financial Trims Cytokinetics (NASDAQ:CYTK) Target Price to $70.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective lowered by Truist Financial from $86.00 to $70.00 in a research report released on Wednesday morning, Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on CYTK. JMP Securities cut their price […] ....

Fady Ibraham Malik , Johnt Henderson , Raymond James , Cytokinetics Incorporated , Bessemer Group Inc , Cytokinetics Company Profile , Fifth Third Bancorp , Securities Exchange Commission , Third Bancorp , Entrypoint Capital , Sage Rhino Capital , Free Report , Truist Financial , Moderate Buy , Stock Down , Get Free Report , Director John , Exchange Commission , Ibraham Malik , Point Capital , Cytokinetics Daily ,

Cytokinetics (NASDAQ:CYTK) PT Lowered to $78.00 at JMP Securities

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target decreased by JMP Securities from $106.00 to $78.00 in a research note issued to investors on Tuesday, Benzinga reports. JMP Securities currently has a market outperform rating on the biopharmaceutical company’s stock. CYTK has been the subject of a number of other reports. Mizuho dropped their […] ....

Johnt Henderson , Fady Ibraham Malik , Raymond James , Needham Company , Bessemer Group Inc , Entrypoint Capital , Third Bancorp , Cytokinetics Company Profile , Sage Rhino Capital , Fifth Third Bancorp , Cytokinetics Incorporated , Free Report , Moderate Buy , Get Free Report , Director John , Ibraham Malik , Point Capital , Cytokinetics Daily ,

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have been given an average rating of “Moderate Buy” by the seventeen brokerages that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 […] ....

United States , Johnt Henderson , Fady Ibraham Malik , Financial Services Group Inc , Mutual Of America Capital Management , Fifth Third Bancorp , Needham Company , Third Bancorp , Cytokinetics Incorporated , Quadrant Capital Group , Get Free Report , Marketbeat Ratings , Director John , Ibraham Malik , State Retirement , Pension System , Capital Group , America Capital Management , Services Group , Get Free , Cytokinetics Daily ,

Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by Analysts

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has received an average recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 1-year target price among analysts […] ....

United States , Johnt Henderson , Fady Ibraham Malik , Mutual Of America Capital Management , Third Bancorp , Cytokinetics Incorporated , Securities Exchange Commission , Fifth Third Bancorp , Quadrant Capital Group , Financial Services Group Inc , Get Free Report , Truist Financial , Director John , Exchange Commission , Ibraham Malik , State Retirement , Pension System , Capital Group , America Capital Management , Services Group , Stock Down , Get Free , Cytokinetics Daily ,

Truist Financial Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $70.00

Cytokinetics (NASDAQ:CYTK – Get Free Report) had its target price decreased by equities research analysts at Truist Financial from $86.00 to $70.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price target would indicate a potential upside of 45.20% from […] ....

Johnt Henderson , Fady Ibraham Malik , Needham Company , Third Bancorp , Fifth Third Bancorp , Bessemer Group Inc , Securities Exchange Commission , Cytokinetics Incorporated , Entrypoint Capital , Sage Rhino Capital , Get Free Report , Truist Financial , Ibraham Malik , Exchange Commission , Director John , Point Capital , Cytokinetics Daily ,